Facility footprint
Animal models
Number of clients
Professional Staff
KCI Biotech is a full service preclinical CRO with 40,000+㎡ of AAALAC-accredited facilities. Our platforms support multiple species, 500+ disease models, and BSL-2/ABSL-2 pathogen research covering 100+ microorganisms, along with pathology and toxicology services. With 1,000+ partners and 200+ regulatory projects, we are recognized among the top preclinical CRO companies for comprehensive drug development expertise.
KCI Biotech provides a full range of preclinical new drug development services for global pharmaceutical companies and research institutions. Our full service preclinical CRO platform establishes a professional and efficient drug development evaluation system.
As a professional One-Stop preclinical CRO，Our integrated R&D team has extensive experience in in vivo pharmacology and pharmacodynamics evaluation. Adhering to a professional spirit of integrity and excellence, we provide comprehensive preclinical drug development services to global pharmaceutical companies and research institutions.
We value your CRO consulting needs and are committed to providing customized solutions to meet your drug discovery and development needs. If you have any questions, need more information, or are interested in exploring potential collaboration opportunities, simply leave a message and our team of experts will be at your service.
Suzhou site
Small Animal Laboratory
10000㎡
Nantong-Haimen site
Large Animal Laboratory
7600㎡
Nantong-Haimen site
Animal Breeding Center
22400㎡
Explore our science sharing series on animal models and assay methodologies, along with recent client successes, delivered by a trusted preclinical efficacy CRO.
Introduction In the field of life sciences and medical research, 3D cell culture technology is quietly transforming our understanding of the cellular world. Unlike conventional
Introduction SSTI Skin and soft tissue infections (SSTI) represent one of the most common spectrums of infectious diseases in clinical practice, with a wide range of
Introduction CRPV Human papillomavirus (HPV) infection represents a major global public health challenge with high prevalence. Persistent infection with high-risk HPV can induce malignant lesions
1Introduction In August 2026, a milestone breakthrough was achieved in hepatitis B treatment. Japan’s Ministry of Health, Labour and Welfare approved the launch of bepirovirsen
01 Background Allergic Rhinitis Allergic Rhinitis (AR) is an IgE‑mediated chronic inflammatory disease of the nasal mucosa, mainly manifested by symptoms such as nasal pruritus, sneezing, rhinorrhea and
1Warm congratulations Recently, Parr Bio’s independently developed world’s first influenza vaccine containing CpG adjuvant (Project Code: HP-3001) has been approved by the National Medical Products Administration (NMPA). As an
From Inquiry, documentation, execution, QC/CA to Report.
See the chart of our cooperation steps. Feel free to contact our team and set a meeting together.
ELISA, FACS Analysis, LC/MS/MS, etc.
Yes. Our facilities are AAALAC-accredited and operate under a strict quality system. With our professional CRO expert team’s support, we provides reliable preclinical pharmacology and drug evaluation technical services for pharmaceutical research and development,hoping to help you accelerate the process of new drug development.
We have internationally advanced laboratory animal facilities certified by AAALAC in Suzhou and Nantong , as well as a 22400 m2 international advanced-level laboratory animal breeding center,with a total area of over 40,000m2 capabilities for meeting the needs of various preclinical experimental studies.
We maintain a comprehensive laboratory animal platform, from rodents to non-human primates, over 500 established disease models,enabling diverse preclinical efficacy studies,including mice, hamsters, guinea pigs, rabbits, cats, dogs, pigs, ferrets, and non-human primates.
To further address highly complex research requirements, as a full service preclinical CRO , we equipped with advanced BSL-2/ABSL-2 anti-infection research and development service platform for human drugs, veterinary drugs, and pet drug development research., multiple service platforms for pathology, toxicology, pharmacokinetics, cell and molecular biology, as well as medical imaging system.
Comprehensive preclinical drug development and service platform
Building A2, No, 8 Yanghua road, Suzhou industrial Park, Suzhou.P.R, china
